scPharmaceuticals

scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include FUROSCIX, a furosemide injection which is used as parenteral diuretic in treating heart failure and scCeftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

scPharmaceuticals reports Q4 loss, sees growth potential with FUROSCIX

scPharmaceuticals' financials show investment in the FUROSCIX launch, with a net loss reported for Q4 2022 and the full year.
FUROSCIX's commercial success, distribution partnerships, and evolving physician perceptions are key strengths for the company.
Challenges lie in reimbursement processes, achieving target co-pays, and aligning on optimal FUROSCIX use timing among doctors.
Opportunities include the substantial market potential, targeted outreach to hospitals, and driving prescriptions through in-services.

scPharmaceuticals reports mixed Q1 results, FUROSCIX shows promising market reception

scPharmaceuticals reported mixed financials with strong revenue but a net loss in Q1 2023.
FUROSCIX's success in the market and positive feedback position it well for future growth.
Challenges exist in managing expenses and securing broader coverage for the treatment.
Opportunities lie in expanding patient access, improving authorization rates, and driving revenue growth.

scPharmaceuticals reports $1.6M Q2 revenue, eyes FDA filing expansion

scPharmaceuticals (SCPH) reported mixed financial results for Q2, with strong revenue but a net loss. The company is focused on expanding FUROSCIX's market reach, improving gross to net discount, and enhancing brand awareness through marketing efforts. Anticipated FDA filing and plans for indication expansion signal growth potential.

scPharmaceuticals reports stellar Q3 performance, eyes market expansion opportunities

scPharmaceuticals delivered robust financial results in Q3 2023, driven by strong revenue growth and improved gross profit margins.
Strategic initiatives to expand market reach and access to FUROSCIX position the company for sustained growth and market penetration.
While facing challenges in pricing dynamics and regulatory expansions, scPharmaceuticals holds significant opportunities for growth and value creation.

scPharmaceuticals reports strong Q4 earnings and eyes market expansion

scPharmaceuticals showcased robust financial performance and strategic growth initiatives in Q4 2023, driven by FUROSCIX sales.
While facing market complexities and operational challenges, the company maintains a strong cash position and optimistic outlook for future initiatives.
Opportunities lie in market access negotiations, streamlined regulatory processes, and expanding product coverage, positioning scPharmaceuticals for continued success.

scPharmaceuticals reports Q1 challenges but remains optimistic for 2024

scPharmaceuticals faced challenges in Q1 due to a cyber attack and increased expenses, but showed resilience with positive trends in FUROSCIX utilization and growth initiatives. The company remains optimistic for continued momentum and life cycle initiatives in 2024.

scPharmaceuticals reports robust Q2 performance and regulatory wins

scPharmaceuticals delivered strong financial performance and regulatory milestones in Q2 2024, positioning the company for growth.
While facing operational challenges and competitive pressures, the company's strategic strengths and opportunities offer avenues for future success.
With a focus on innovation, market expansion, and financial stability, scPharmaceuticals is poised for continued growth and value creation.
Investors can be optimistic about scPharmaceuticals' progress and potential in the pharmaceutical market based on the Q2 performance and strategic initiatives.

scPharmaceuticals reports revenue growth and strategic advancements in Q3

scPharmaceuticals demonstrated revenue growth and strategic advancements in Q3 2024, underpinned by strong FUROSCIX sales and key initiatives.
While facing challenges such as ongoing losses and pricing dynamics, the company's focus on innovation and commercial progress positions it well for future growth.
With opportunities in seasonal demand, market expansion, and a solid financial base, scPharmaceuticals is poised for continued development and value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

scPharmaceuticals received a second Complete Response Letter (CRL) on Furoscix rather than an FDA approval in December of 2020. The issues in the CRL are being addressed. The subcutaneous, home delivery of tried-and-true drugs offers a convenient and compelling value proposition likely to be attractive to patients, physicians and payers.

ScPharmaceuticals: The Third Time's A Charm

FREEDOM clinical study on track for topline results in Q3 2021

scPharmaceuticals Inc. Reports First Quarter 2021 Financial Results and Provides Business Update

ScPharmaceuticals Inc (NASDAQ: SCPH) announced that after the Type A meeting with the FDA, the agency does not require any modifications to the device, nor it asked the company to conduct additional clinical studies to demonstrate the safety and efficacy of Furoscix. In December last year, the company received a Complete Response Letter due to the FDA's inability to conduct pre-approval inspections at two of scPharma's third-party manufacturing facilities due to travel restrictions.

ScPharmaceuticals Sees US Application Submission For Furoscix In Q3

BURLINGTON, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced the appointment of William T. Abraham, M.D., to the company's Board of Directors. Dr. Abraham currently serves as Professor of Internal Medicine (Cardiology), Physiology and Cell Biology and College of Medicine Distinguished Professor at The Ohio State University as well as Chief Medical Officer at V-Wave Ltd., a privately held developer of percutaneous implantable therapeutic devices for chronic heart failure patients.

scPharmaceuticals Inc. Appoints Renowned Heart Failure Specialist William T. Abraham, M.D.

BURLINGTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24 at 11:20 EDT.

scPharmaceuticals to Present at the 10th Annual SVB Leerink Global Healthcare Conference

NEW YORK, Dec. 10, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of scPharmaceuticals Inc. ("scPharmaceuticals" or the "Company") (NASDAQ: SCPH). uch investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext....

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of scPharmaceuticals Inc. - SCPH

scPharmaceuticals (SCPH) receives complete response letter from the FDA regarding an NDA for its pipeline candidate, Furoscix, as a potential treatment for congestion due to fluid overload in adult patients.

scPharmaceuticals (SCPH) Plunges on Complete Response Letter

Scpharmaceuticals Inc (NASDAQ: SCPH) shares were hurtling toward their late March lows Monday after a binary event panned out negatively for the biopharma. What Happened: Burlington, Massachusetts-based scPharma said the FDA issued a complete response letter for its new drug application for Furoscix, a proprietary, subcutaneously delivered furosemide solution being evaluated as an outpatient alternative for the treatment of worsening congestive heart failure.

FDA Rejects scPharma's Heart Failure Drug For Second Time, Sending Biotech Stock Lower

BURLINGTON, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the 3rd Annual Evercore ISI Virtual HealthCONx Conference on Thursday, December 3 at 11:20am EST.

scPharmaceuticals to Present at the 3rd Annual Evercore ISI Virtual HealthCONx Conference

Commercial ization preparedness activities continuing ahead of December 30 PDUFA date for FUROS C IX ® (furosemide injection) for subcutaneous administration

scPharmaceuticals Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update

BURLINGTON, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the Jefferies Virtual London Healthcare Conference on Wednesday, November 18 at 12:35 EDT / 5:35 GMT.

scPharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference

scPharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

scPharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

scPharmaceuticals has created proprietary formulations of widely used, generically available IV drugs that can be more easily administered subcutaneously.

scPharmaceuticals - An Undervalued, Under The Radar Biotech

The pharmaceutical company priced a secondary offering to raise capital.

Why scPharmaceuticals Stock Plunged Today

Continued progress on FUROSCIX; confirming the planned  resubmission of FUROSCIX NDA with the FDA by mid-year 2020

News for scPharmaceuticals Stock (SCPH)